The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 6, 2009, Pages 665-674

  Spears, Melanie ^a   Bartlett, John ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

AIB1; Breast cancer; Estrogen receptor; SRC 1; SRC 2

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BRCA1 PROTEIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EVEROLIMUS; EXEMESTANE; NUCLEAR RECEPTOR COACTIVATOR 2; PLACEBO; PROTEIN TYROSINE KINASE; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; HUMAN; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; HUMANS; LIGANDS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 67649588929     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220902911509     Document Type: Review

References (101)

1. Chen GG, Zeng Q, Tse GM. Estrogen and its receptors in cancer. Med Res Rev 2008;28(6):954-974
2. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001;7(12 Suppl): 4338s-42s; discussion 4411s-4412s (Pubitemid 34031577)
3. Menasce LP, White GR, Harrison CJ, Boyle JM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993;17(1):263-265 (Pubitemid 23205095)
4. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82(12):4258-4265 (Pubitemid 27525550)
5. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87(3):905-931 (Pubitemid 47084672)
6. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and aβ. Endocrinology 1997;138(3):863-870 (Pubitemid 27089735)
7. Simpkins JW, Yang SH, Sarkar SN, Pearce V. Estrogen actions on mitochondria-physiological and pathological implications. Mol Cell Endocrinol 2008;290(1-2):51-59
8. Neuman E, Ladha MH, Lin N, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 1997;17(9):5338-5347 (Pubitemid 27357632)
9. Okada S, Yamauchi K, Pessin JE. Shc isoform-specific tyrosine phosphorylation by the insulin and epidermal growth factor receptors. J Biol Chem 1995;270(35):20737-20741
10. Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8(3):187-198 •• Good review of the PI3K/Akt pathway. (Pubitemid 351688437)
11. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem 2001;276(13):9817-9824 (Pubitemid 37391881)
12. Jackson TA, Richer JK, Bain DL, et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997;11(6):693-705 (Pubitemid 27225297)
13. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270(5241):1491-1494
14. Lannigan DA. Estrogen receptor phosphorylation. Steroids 2003;68(1):1-9 (Pubitemid 35418300)
15. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2002;76(1):27-36 (Pubitemid 35178626)
16. Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer-the present. Histopathology 2008;52(1):82-90 (Pubitemid 350265187)
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-1717 (Pubitemid 40719106)
18. Nicholson RI, Hutcheson IR, Harper ME, et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001;8(3):175-182 (Pubitemid 32947639)
19. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23(8):1616-1622 (Pubitemid 46211414)
20. Osborne CK, Wiebe VJ, McGuire WL, et al. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 1992;10(2):304-310
21. Tovey S, Dunne B, Witton CJ, et al. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005;11(13):4835-4842
22. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004;91(8):1532-1542 (Pubitemid 39486359)
23. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68(3):826-833 (Pubitemid 351206760)
24. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200(3):290-297 (Pubitemid 36827302)
25. Gutierrez MC, Detre S, Johnston S, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23(11):2469-2476 (Pubitemid 47050837)
26. Kirkegaard T, Witton CJ, McGlynn LM, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005;207(2):139-146 (Pubitemid 41404144)
27. Spears M, Kenicer J, Munro AF, Bartlett JMS. Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer. Biomark Med 2008;2:397-407
28. Johnston SR, Saccani-Jotti G, Smith IE, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995;55(15):3331-3338
29. Kirkegaard T, McGlynn LM, Campbell FM. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 2007;13(5):1405-1411 • Shows the role of AIB1 in breast cancer. (Pubitemid 46450429)
30. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95(5):353-361 (Pubitemid 36395255)
31. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11(4):643-658 • Good review of tamoxifen resistance. (Pubitemid 40065543)
32. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57(22):4987-4991 (Pubitemid 27498105)
33. Fuqua SA. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2001;6(4):407-417 (Pubitemid 39600498)
34. Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284(5418):1354-1356 (Pubitemid 29289660)
35. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20(9):2310-2318 (Pubitemid 34441658)
36. Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004;6(1):R8-R17
37. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351(9099):316-321 (Pubitemid 28052696)
38. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356(9245):1876-1881
39. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 1998;247(1):75-78 (Pubitemid 28412528)
40. Poola I, Abraham J, Baldwin K, et al. Estrogen receptors beta4 and beta5 are full length functionally distinct ERaβ isoforms: cloning from human ovary and functional characterization. Endocrine 2005;27(3):227-238 (Pubitemid 41456738)
41. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-β isoforms: a key to understanding ER-β signaling. Proc Natl Acad Sci USA 2006;103(35):13162-13167 (Pubitemid 44338933)
42. Dotzlaw H, Leygue E, Watson PH, Murphy LC. Expression of estrogen receptor-β in human breast tumors. J Clin Endocrinol Metab 1997;82(7):2371-2374 (Pubitemid 27287615)
43. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000;156(1):29-35 (Pubitemid 30644435)
44. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, et al. Increased estrogen receptor βcx expression during mammary carcinogenesis. Clin Cancer Res 2005;11(9):3170-3174 (Pubitemid 40637201)
45. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. Estrogen receptor β (ERaβ) level but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004;10(17):5769-5776
46. Jarzabek K, Koda M, Kozlowski L, et al. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors α and β in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer 2005;41(18):2924-2934 (Pubitemid 41713133)
47. Omoto Y, Kobayashi S, Inoue S, et al. Evaluation of oestrogen receptor β wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 2002;38(3):380-386 (Pubitemid 34123315)
48. Skliris G, Carder PJ, Lansdown MR, Speirs V. Immunohistochemical detection ERβ in breast cancer: towards more detailed receptor profiling? Br J Cancer 2001;84(8):1095-1098
49. Speirs V, Malone C, Walton DS, et al. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999;59(21):5421-5424 (Pubitemid 29526448)
50. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14(2):121-141 (Pubitemid 30070977)
51. Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 1998;95(6):2920-2925 (Pubitemid 28135830)
52. Available from: www.NURSA.org
53. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. Clin Oncol 2007;25(36):5815-5824
54. Kurebayashi J, Otsuki T, Kunisue H, et al. Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000;6(2):512-518 (Pubitemid 30111472)
55. Huang ZJ, Edery I, Rosbash M. PAS is a dimerization domain common to Drosophila period and several transcription factors. Nature 1993;364(6434):259- 262 (Pubitemid 23257088)
56. Chen H, Lin RJ, Schiltz RL, et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997;90(3):569-580 (Pubitemid 27347246)
57. Li J, O'Malley BW, Wong J. p300 requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin. Mol Cell Biol 2000;20(6):2031-2042 (Pubitemid 30123819)
58. Voegel JJ, Heine MJ, Tini M, et al. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 1998;17(2):507-519 (Pubitemid 28045491)
59. Lonard DM, O'Malley BW. Expanding functional diversity of the coactivators. Trends Biochem Sci 2005;30(3):126-132 (Pubitemid 40332528)
60. Wu RC, Qin J, Yi P, et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell 2004;15(6):937-949 (Pubitemid 39277990)
61. Gnanapragasam VJ, Leung HY, Pulimood AS, et al. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001;85(12):1928-1936 (Pubitemid 34775331)
62. Bautista S, Vallès H, Walker RL, et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 1998;4(12):2925-2929
63. Torres-Arzayus MI, Font de Mora J, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6(3):263-274 (Pubitemid 39222039)
64. Kuang SQ, Liao L, Zhang H, et al. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 2004;64(5):1875-1885 (Pubitemid 38428714)
65. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20(14):5041-5047 •• Good research paper detailing mechanistic function. (Pubitemid 30431558)
66. Fleming FJ, Myers E, Kelly G, et al. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol 2004;57(10):1069-1074 (Pubitemid 39331358)
67. Fleming FJ, Hill AD, McDermott EW, et al. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by β-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab 2004;89(1):375-383 (Pubitemid 38183907)
68. Myers E, Hill AD, Kelly G, et al. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res 2005;11(6):2111-2122 (Pubitemid 40490167)
69. Weiss RE, Xu J, Ning G, et al. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 1999;18(7):1900-1904 (Pubitemid 29158533)
70. Kotaja N, Karvonen U, Jänne OA, Palvimo JJ. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 2002;277(33):30283-30288
71. Kotaja N, Vihinen M, Palvimo JJ, Janne OA. Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling. J Biol Chem 2002;277(20):17781-17788 (Pubitemid 34967585)
72. Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004;279(8):7119-7130 (Pubitemid 38248859)
73. Lopez GN, Turck CW, Schaufele F, et al. Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J Biol Chem 2001;276(25):22177-22182 (Pubitemid 37410885)
74. Børud B, Hoang T, Bakke M, et al. The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1. Mol Endocrinol 2002;16(4):757-773 (Pubitemid 34297745)
75. Hoang T, Fenne IS, Cook C, et al. cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. J Biol Chem 2004;279(47):49120-49130 (Pubitemid 39625795)
76. Picard F, Géhin M, Annicotte J, et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 2002;111(7):931-941 (Pubitemid 36044686)
77. Gehin M, Mark M, Dennefeld C, et al. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol 2002;22(16):5923-5937 (Pubitemid 34815840)
78. Normanno N, Di Maio M, De Maio E, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005;12(4):721-747 (Pubitemid 41815773)
79. Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988;55(1):145-156 (Pubitemid 18243642)
80. Lonard DM, O'Malley BW. The expanding cosmos of nuclear receptor coactivators. Cell 2006;125(3):411-414
81. Metivier R, Penot G, Hubner MR, et al. Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003;115(6):751-763 (Pubitemid 38030303)
82. Shang Y, Hu X, DiRenzo J, et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000;103(6):843-852
83. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000;74(5):311-317 (Pubitemid 32126243)
84. Levin ER. Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 2008;108(3):351-361
85. Borg A, Baldetorp B, Fernö M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81(2):137-144 (Pubitemid 24184647)
86. Park KJ, Krishnan V, O'Malley BW, et al. Formation of an IKKα-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 2005;18(1):71-82 (Pubitemid 40444649)
87. Zhou G, Hashimoto Y, Kwak I, et al. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 2003;23(21):7742-7755 (Pubitemid 37271472)
88. Yan J, Yu CT, Ozen M, et al. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 2006;66(22):11039-11046 (Pubitemid 44877004)
89. Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 2004;24(12):5157-5171 (Pubitemid 38738153)
90. Miller WR, Bartlett JM, Canney P, Verrill M. Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res Treat 2007;103(2):149-160 (Pubitemid 46789136)
91. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006;13(Suppl 1):S15-24 (Pubitemid 46219245)
92. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11(2 Pt 2):865s-70s (Pubitemid 40111098)
93. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J Clin Oncol 2001;19(18):3808-3816 (Pubitemid 32880059)
94. Schiff R, Massarweh SA, Shou J, et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10(1 Pt 2):331S-6S (Pubitemid 38116639)
95. Bijl MJ, van Schaik RH, Lammers LA, et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009; published online 3 February 2009, doi: 10.1007/s10549-008-0272-2
96. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101(1):113-121 (Pubitemid 47555336)
97. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23(30):7512-7517 (Pubitemid 46291814)
98. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9(1):23-28
99. Wu RC, Qin J, Hashimoto Y, et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by IκB kinase. Mol Cell Biol 2002;22(10):3549-3561 (Pubitemid 34453993)
100. Horiguchi K, Arai S, Nishihara T, Nishikawa J. AIB1 promotes DNA replication by JNK repression and AKT activation during cellular stress. J Biochem 2006;140(3):409-419 (Pubitemid 44703159)
101. Torres-Arzayus MI, Yuan J, Dellagatta JL, et al. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. Cancer Res 2006;66(23):11381-11388 • Good research article providing potential treatment target. (Pubitemid 46009969)